Free tool
FAERS Monitor: Neostigmine Methylsulfate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203629 or its brand name (Neostigmine Methylsulfate, Neostigmine Methylsulfate). Reports on generic versions are filed under their own applications.
Reports
365
Serious
331
91% of reports
Hospitalization
156
Death reported
53
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective34
- abdominal distension25
- nausea23
- hypotension22
- respiratory failure20
- abdominal pain19
- white blood cell count increased18
- cardiac arrest16
- pyrexia16
- bradycardia15
- generalised tonic-clonic seizure15
- subileus15
- febrile neutropenia14
- pulmonary oedema14
- renal ischaemia14
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 5 |
| 2006 | 6 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 6 |
| 2010 | 5 |
| 2011 | 3 |
| 2012 | 16 |
| 2013 | 9 |
| 2014 | 16 |
| 2015 | 11 |
| 2016 | 23 |
| 2017 | 19 |
| 2018 | 25 |
| 2019 | 26 |
| 2020 | 20 |
| 2021 | 20 |
| 2022 | 29 |
| 2023 | 34 |
| 2024 | 45 |
| 2025 | 29 |
| 2026 | 11 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,794 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| renal ischaemiaSignal | 14 | 1515.1 | 900.2 | 19,193 |
| subileusSignal | 15 | 418.2 | 254.3 | 5,791 |
| generalised tonic-clonic seizureSignal | 15 | 52.3 | 31.8 | 704 |
| white blood cell count increasedSignal | 18 | 27.1 | 17.2 | 426 |
| pulmonary oedemaSignal | 14 | 18.0 | 10.8 | 209 |
| bradycardiaSignal | 15 | 16.3 | 9.9 | 201 |
| respiratory failureSignal | 20 | 15.8 | 10.3 | 264 |
| abdominal distensionSignal | 25 | 13.8 | 9.5 | 286 |
| febrile neutropeniaSignal | 14 | 12.2 | 7.3 | 133 |
| cardiac arrestSignal | 16 | 11.2 | 6.9 | 139 |
| hypotensionSignal | 22 | 6.3 | 4.2 | 94 |
| abdominal painSignal | 19 | 4.7 | 3.0 | 52 |
| pyrexiaSignal | 16 | 2.7 | 1.7 | 15 |
| nausea | 23 | 1.7 | 1.1 | 6 |
| drug ineffective | 34 | 1.5 | 1.1 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.